WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
AbbottCaring for the world one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

www.jnj.com

Johnson & Johnson RSS Channel

List of articles in category Johnson & Johnson
Title Published Date
Johnson & Johnson COVID-19 vaccine named one of Time's Best Inventions of 2021 12 November 2021
17 million doses of Johnson & Johnson COVID-19 vaccine to be donated to African Union countries 19 October 2021
Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response 07 July 2021
Johnson & Johnson statement on COVID-19 vaccine 14 April 2021
Johnson & Johnson announces advance purchase agreement with the African Vaccine Acquisition Trust 29 March 2021
Johnson & Johnson announces aingle-ahot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial 08 March 2021
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of investigational single-shot Janssen COVID-19 vaccine candidate 22 February 2021
Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorization of its investigational single-shot Janssen COVID-19 vaccine candidate 05 February 2021
Johnson & Johnson announces initiation of rolling submission for its single-dose Janssen COVID-19 vaccine candidate with the European Medicines Agency 04 December 2020
Johnson & Johnson initiates second global Phase 3 clinical trial of its Janssen COVID-19 vaccine candidate 26 November 2020
Johnson & Johnson prepares to resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 vaccine candidate in the U.S. 26 October 2020
Johnson & Johnson announces European Commission approval of agreement to supply 200 million doses of Janssen's COVID-19 vaccine candidate 08 October 2020
Johnson & Johnson initiates pivotal global Phase 3 clinical trial of Janssen's COVID-19 vaccine candidate 28 September 2020
Johnson & Johnson announces that Janssen's COVID-19 investigational vaccine candidate prevents severe clinical disease in pre-clinical studies 07 September 2020
Johnson & Johnson announces agreement with U.S. government for 100 million doses of investigational COVID-19 vaccine 13 August 2020
Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies 30 July 2020
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July 10 June 2020
Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate 18 May 2020
Johnson & Johnson announces a lead vaccine candidate for COVID-19 07 April 2020
Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza 18 September 2017
  • Start
  • Prev
  • 1
  • 2
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Johnson & Johnson

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.